DD139855A5 - Verfahren zur herstellung von xanthinderivaten - Google Patents

Verfahren zur herstellung von xanthinderivaten Download PDF

Info

Publication number
DD139855A5
DD139855A5 DD78208423A DD20842378A DD139855A5 DD 139855 A5 DD139855 A5 DD 139855A5 DD 78208423 A DD78208423 A DD 78208423A DD 20842378 A DD20842378 A DD 20842378A DD 139855 A5 DD139855 A5 DD 139855A5
Authority
DD
German Democratic Republic
Prior art keywords
methyl
compound
preparation
compounds
added
Prior art date
Application number
DD78208423A
Other languages
German (de)
English (en)
Inventor
Sten H Bergstrand
Per G Kjellin
Carl G Persson
Lars M Soerenby
Original Assignee
Draco Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Draco Ab filed Critical Draco Ab
Publication of DD139855A5 publication Critical patent/DD139855A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DD78208423A 1977-10-14 1978-10-12 Verfahren zur herstellung von xanthinderivaten DD139855A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7711581A SE416810C (sv) 1977-10-14 1977-10-14 Forfarande for framstellning av xantinderivat med antiallergisk aktivitet

Publications (1)

Publication Number Publication Date
DD139855A5 true DD139855A5 (de) 1980-01-23

Family

ID=20332576

Family Applications (1)

Application Number Title Priority Date Filing Date
DD78208423A DD139855A5 (de) 1977-10-14 1978-10-12 Verfahren zur herstellung von xanthinderivaten

Country Status (21)

Country Link
US (1) US4233303A (it)
EP (1) EP0001735B1 (it)
JP (1) JPS5479296A (it)
AT (1) AT363491B (it)
AU (1) AU521585B2 (it)
CA (1) CA1109470A (it)
CS (1) CS208756B2 (it)
DD (1) DD139855A5 (it)
DE (1) DE2862017D1 (it)
DK (1) DK148260C (it)
FI (1) FI66383C (it)
HK (1) HK6385A (it)
HU (1) HU180219B (it)
IE (1) IE47884B1 (it)
IT (1) IT1109208B (it)
NO (1) NO147562C (it)
NZ (1) NZ188566A (it)
SE (1) SE416810C (it)
SG (1) SG85584G (it)
SU (1) SU755199A3 (it)
ZA (1) ZA785335B (it)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
SE8002910L (sv) * 1980-04-18 1981-10-19 Draco Ab 3,8-dialkylxantiner, forfarande for deras framstellning, beredning och metoder for behandling av kronisk obstruktiv luftvegssjukdom och kardiovaskulera sjukdomar
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
GB8929208D0 (en) * 1989-12-27 1990-02-28 Almirall Lab New xanthine derivatives
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5342841A (en) * 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5366977A (en) * 1992-09-29 1994-11-22 The United States Of America, As Represented By The Department Of Health And Human Services Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
ATE247655T1 (de) * 1994-12-13 2003-09-15 Euro Celtique Sa Dreifachsubstituierte thioxanthine
EP0814809B1 (en) * 1994-12-13 2003-08-13 Euroceltique S.A. Aryl thioxanthines
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) * 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
AU2004233852A1 (en) 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
WO2005105083A1 (en) * 2004-04-16 2005-11-10 Novacardia, Inc. Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
US20070049757A1 (en) * 2005-08-26 2007-03-01 Rieger Jayson M Methods for the synthesis of substituted amino uracils

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1911279A1 (de) * 1969-03-05 1970-11-12 Eckert Dr Theodor Verfahren zur Erhoehung der Resorptionsfaehigkeit von Arzneistoffen
US3900474A (en) * 1973-05-14 1975-08-19 Kendall & Co Trifluoroalkyl, fluorobenzyl, pentafluorobenzyl, fluorobenzenesulfonyl, and pentafluorobenzenesulfonyl theophyllines
US4061753A (en) * 1976-02-06 1977-12-06 Interx Research Corporation Treating psoriasis with transient pro-drug forms of xanthine derivatives
CA1077932A (en) 1976-03-31 1980-05-20 Berlex Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases

Also Published As

Publication number Publication date
US4233303A (en) 1980-11-11
ZA785335B (en) 1979-09-26
IT1109208B (it) 1985-12-16
CS208756B2 (en) 1981-09-15
NZ188566A (en) 1984-07-06
IT7851499A0 (it) 1978-10-13
SE7711581L (sv) 1979-04-15
DE2862017D1 (en) 1982-10-28
SU755199A3 (en) 1980-08-07
IE47884B1 (en) 1984-07-11
DK453778A (da) 1979-04-15
FI66383B (fi) 1984-06-29
FI783126A (fi) 1979-04-15
SG85584G (en) 1985-06-07
ATA714478A (de) 1980-09-15
NO147562C (no) 1983-05-18
SE416810B (sv) 1981-02-09
AT363491B (de) 1981-08-10
IE782041L (en) 1979-04-14
EP0001735A1 (en) 1979-05-02
CA1109470A (en) 1981-09-22
DK148260C (da) 1986-02-10
SE416810C (sv) 1982-07-19
AU4036578A (en) 1980-04-17
HK6385A (en) 1985-02-01
DK148260B (da) 1985-05-20
EP0001735B1 (en) 1982-09-01
JPS5479296A (en) 1979-06-25
NO147562B (no) 1983-01-24
NO783471L (no) 1979-04-18
AU521585B2 (en) 1982-04-22
FI66383C (fi) 1984-10-10
HU180219B (en) 1983-02-28

Similar Documents

Publication Publication Date Title
DD139855A5 (de) Verfahren zur herstellung von xanthinderivaten
DE2915318C2 (it)
DD146708A5 (de) Verfahren zur herstellung von 3-alkylxanthinen
EP0011609B1 (en) Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease
CH625522A5 (it)
DE3406275A1 (de) Neue adenosinrezeptoren-antagonisten
DE2713389C2 (it)
DE2164058C3 (de) Basisch substituierte Benzylphthalazinon-Derivate, ihre Salze, Verfahren zu ihrer Herstellung und diese Produkte enthaltende pharmazeutische Präparate
DD158776A5 (de) Verfahren zur herstellung von di-oder triesubstituiertenxanthinen
DE3307395A1 (de) Arzneimittel zur behandlung von schmerzen, fieber, gewebe- und/oder knochen- und gelenkentzuendungen mit einem gehalt an theobromin- oder theophyllinderivaten als aktivem bestandteil
DE2720545C3 (de) Derivate des 2,4-Diamino-6,7-dimethoxychinazolins, ihre Herstellung und pharmazeutische Mittel
DE2640972A1 (de) Aminoaethanolderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
CH634574A5 (de) Verfahren zur herstellung von 7-(2,3-dihydroxypropyl)-1,3-di-n-propylxanthin.
DE2460929C2 (it)
DE2900288A1 (de) Aminoderivate von pyrazol eckige klammer auf 1,5-a eckige klammer zu s-triazin, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE3043979C2 (de) N-(5-Tetrazolyl)-1-oxo-1H-thiazolo-[3,2-a]-pyrimidin-2-carboxamide
DE3785076T2 (de) Pyrido(4,3-d)pyrimidin-derivate.
DE3541428A1 (de) Neue basisch substituierte pyridinverbindungen, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
DE2806199A1 (de) Aminopyrimidinverbindungen, verfahren zu ihrer herstellung und arzneimittel
DE2253914A1 (de) Neue chromonderivate und verfahren zu ihrer herstellung
DE2755707A1 (de) Verfahren zur herstellung von neuen piperazinderivaten
EP0557877B1 (de) Lösliche Salze von 4-Amino-2-(4,4-dimethyl-imidazolidin-2-on-1-yl)-pyrimidin-5 -carbonsäure- N-methyl-N-(3-trifluormethyl-phenyl)- amid, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und Ausgangsprodukte
DE4411660A1 (de) Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DE2435381C2 (de) 8-(2-Dimethylaminoäthyl)-3-oxo-4-phenyl-1-thia-4,8-diazaspiro[4.5]decan und seine Salze mit Säuren, Verfahren zu ihrer Herstellung und deren Verwendung in Arzneipräparaten
DE3017560A1 (de) 9-amino-6,7-dihydro-4h-pyrido eckige klammer auf 1,2-a eckige klammer zu pyrimidin-4-on-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische kompositionen